Ozdogan H, Ugurlu S. Canakinumab for the treatment of familial Mediterranean fever. Expert Rev Clin Immunol. 2017:1–12.
https://doi.org/10.1080/1744666X.2017.1313116
When the above article was first published online, there were errors in the affiliations and in sections ‘Abstract’, ‘4.3. Phase III trial with canakinumab’, ‘7. Regulatory affairs’, ‘8. Expert commentary and 5-year perspective’ and ‘Key issues’. These have been corrected in both print and online versions and have been also been provided below.
Affiliation
Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University, Fatih, Istanbul, Turkey
ABSTRACT
Areas covered: This review focuses on canakinumab, a fully human anti IL-1β antibody, treatment in FMF.
Expert commentary: Canakinumab became the first approved therapy by the Food and Drug Administration for FMF very recently, which highlights its importance as the alternative treatment in FMF.
4.3. Phase III trial with canakinumab
Sixty-three patients with crFMF were eligible for epoch 2 and were randomized to either canakinumab of 150 mg every 4 weeks (n = 31) or placebo (n = 32), while pediatric patients recieved weight-based dosing.
7. Regulatory affairs
Canakinumab (Ilaris®, Novartis) has very recently been licensed by the FDA for the treatment of three new indications: TRAPS, HIDS/MKD, and FMF.
8. Expert commentary and 5-year perspective
Currently there are three anti-IL-1 agents available for this purpose and canakinumab has just been approved for FMF.
Key issues
Canakinumab has very recently been approved for the treatment of FMF by the Food and Drug Administration together with HIDS/MVD and TRAPS.